Black Diamond Therapeutics (BDTX) Competitors $2.22 +0.03 (+1.37%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BDTX vs. VECT, PHAT, TRML, PROK, DNA, ANNX, ATXS, HUMA, PRTC, and ANABShould you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include VectivBio (VECT), Phathom Pharmaceuticals (PHAT), Tourmaline Bio (TRML), ProKidney (PROK), Ginkgo Bioworks (DNA), Annexon (ANNX), Astria Therapeutics (ATXS), Humacyte (HUMA), PureTech Health (PRTC), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry. Black Diamond Therapeutics vs. VectivBio Phathom Pharmaceuticals Tourmaline Bio ProKidney Ginkgo Bioworks Annexon Astria Therapeutics Humacyte PureTech Health AnaptysBio Black Diamond Therapeutics (NASDAQ:BDTX) and VectivBio (NASDAQ:VECT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Does the MarketBeat Community favor BDTX or VECT? Black Diamond Therapeutics received 41 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 43.48% of users gave VectivBio an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5169.86% Underperform Votes2230.14% VectivBioOutperform Votes1043.48% Underperform Votes1356.52% Do analysts rate BDTX or VECT? Black Diamond Therapeutics presently has a consensus target price of $15.50, suggesting a potential upside of 598.20%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in BDTX or VECT? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 9.7% of VectivBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor BDTX or VECT? In the previous week, Black Diamond Therapeutics' average media sentiment score of 1.22 beat VectivBio's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Black Diamond Therapeutics Positive VectivBio Neutral Is BDTX or VECT more profitable? VectivBio's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -68.08% -49.65% VectivBio N/A N/A N/A Which has more volatility and risk, BDTX or VECT? Black Diamond Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Which has stronger earnings and valuation, BDTX or VECT? Black Diamond Therapeutics has higher earnings, but lower revenue than VectivBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$82.44M-$1.33-1.67VectivBio$27.34M20.97-$93.74MN/AN/A SummaryBlack Diamond Therapeutics beats VectivBio on 9 of the 13 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDTX vs. The Competition Export to ExcelMetricBlack Diamond TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.62M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-1.6746.7391.3417.19Price / SalesN/A411.851,117.70116.80Price / CashN/A182.1042.6437.86Price / Book0.983.894.794.78Net Income-$82.44M-$42.21M$120.07M$225.60M7 Day Performance-13.28%-2.14%-1.90%-1.23%1 Month Performance-8.64%4.21%11.45%3.37%1 Year Performance-17.47%18.40%30.63%16.58% Black Diamond Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDTXBlack Diamond Therapeutics2.3642 of 5 stars$2.22+1.4%$15.50+598.2%-16.2%$125.62MN/A-1.6790Positive NewsGap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030PHATPhathom Pharmaceuticals2.9962 of 5 stars$8.35+5.8%$23.00+175.4%-9.3%$570.97M$680,000.00-1.48110TRMLTourmaline Bio2.4402 of 5 stars$22.14+1.5%$54.00+143.9%+8.7%$567.74MN/A-7.7344PROKProKidney2.0368 of 5 stars$1.91+6.1%$4.50+136.2%-15.6%$555.62MN/A-3.553Gap DownDNAGinkgo Bioworks0.5512 of 5 stars$9.64+2.1%$4.58-52.5%N/A$554.11M$251.46M-0.721,218Gap DownANNXAnnexon2.1121 of 5 stars$5.17+16.4%$15.80+205.6%+81.6%$551.09MN/A-4.9060Analyst ForecastNews CoverageGap DownATXSAstria Therapeutics2.0771 of 5 stars$9.68+1.7%$25.60+164.5%+58.0%$546.24MN/A-4.5630News CoverageHUMAHumacyte3.3447 of 5 stars$4.22+2.9%$13.00+208.1%+69.3%$531.13M$1.57M-3.06150Analyst ForecastGap UpPRTCPureTech Health1.9898 of 5 stars$22.10+8.6%$45.00+103.6%+3.8%$529.12M$3.33M0.00100Gap DownHigh Trading VolumeANABAnaptysBio2.3125 of 5 stars$17.10+9.7%$45.09+163.7%-25.4%$520.35M$17.16M-2.80100Analyst Forecast Related Companies and Tools Related Companies VECT Competitors PHAT Competitors TRML Competitors PROK Competitors DNA Competitors ANNX Competitors ATXS Competitors HUMA Competitors PRTC Competitors ANAB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BDTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BDTX Stock Alerts